Skip to main content
Premium Trial:

Request an Annual Quote

OpGen's Acuitas

OpGen has launched an expanded molecular testing and bioinformatics program for detecting and managing gram-negative multi-drug resistant organisms (MDRO). The products and services that the company is offering through its program are designed to help healthcare providers identify and treat infected patients.

Specifically, the company is offering its Acuitas suite of MDRO tests and its Acuitas Lighthouse MDRO management system. The company's Acuitas Resistome test detects approximately 50 antibiotic resistance genes in gram-negative bacteria, while its Acuitas whole-genome sequence analysis service provides high-resolution strain typing and subtyping for a full spectrum of resistance genes. The company has also released an early iteration of its Acuitas Lighthouse MDRO management system, which provides molecular information about patients' resistance profiles and integrates that data with other patient and hospital-wide data to help improve overall patient outcomes and reduce hospital costs. OpGen expects to launch a full web-based version of the Lighthouse management system in the third quarter of 2015.

These new products and services are available from OpGen's CLIA testing laboratory.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.